Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.

@article{Edwards2007EfficacyAS,
  title={Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.},
  author={Keith R. Edwards and Donald R Royall and Linda Hershey and D G Lichter and Ann Marie Hake and Martin Farlow and Florence Pasquier and Stewart Johnson},
  journal={Dementia and geriatric cognitive disorders},
  year={2007},
  volume={23 6},
  pages={401-5}
}
BACKGROUND Dementia with Lewy bodies (DLB) is a common dementia of the elderly. A significant cholinergic deficit has been demonstrated that may be responsive to treatment by cholinesterase inhibitors (ChEIs). METHODS A 24-week, open-label study was designed to assess the efficacy and safety of a ChEI, galantamine, in 50 patients with DLB. RESULTS This study showed beneficial effects with galantamine in 2 of the 3 primary efficacy parameters. The scores on the Neuropsychiatric Inventory… CONTINUE READING